Cosmos Health Inc.

Listed Company

COSMCIK 0001474167NasdaqNon-AcceleratedSmaller ReportingWholesale-Drugs, Proprietaries & Druggists' SundriesNevadaFY ends Dec 31

Period

FY 2025

Revenue

$65.27M

Net Income

$-19.14M

Total Assets

$65.48M

Equity

$18.42M

Shares Out

54.43M

Op. Cash Flow

$-8.45M

COSM$0.24−46.55% · past yearDBEQ Basic

Daily closing prices

Business

Cosmos Health Inc. is a vertically integrated global healthcare group that develops, manufactures, and distributes generic pharmaceuticals, nutraceutical brands, biocides, and medical devices, while operating a telehealth platform and AI-powered drug repurposing technology. The company offers proprietary brands (Sky Premium Life, Mediterranation, C-Sept/C-Scrub), generic medicines across multiple therapeutic areas, and approximately 165 nutraceutical SKUs. Business segments include manufacturing under GMP/EMA certification, full-line pharmaceutical wholesaling with automated distribution, telehealth services via ZipDoctor subscription platform, and R&D in oncology, obesity management, and drug repurposing. Geographic markets are primarily European Union and UK, with growing operations in UAE and North America.

Summary from 10-K filed 2026-04-15

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
REVENUE	65	54	53	50	56
COST OF GOODS SOLD	57	50	49	44	48
GROSS PROFIT	8	4	4	6	8
General and administrative expenses	16	12	20	10	9
Salaries and wages	7	6	5	2	2
Sales and marketing expenses	150,240	354,969	1	630,057	732,545
Research and development costs	519,363	533,293	164,859	—	—
Impairment Charges	162,785	291,980	0	—	—
Depreciation and amortization expense	1	1	614,377	188,890	449,692
TOTAL OPERATING EXPENSES	25	20	26	13	13
LOSS FROM OPERATIONS	−17	−16	−22	−7	−5
Other income (expense), net	−233,443	86,737	−65,867	−2	−88,882
Interest expense	−2	−1	−866,476	−2	−3
Interest income	396,413	406,449	662,859	236,349	46,316
Gain on equity investments, net	21,368	2,470	—	—	—
Gain on extinguishment of debt	68,610	0	—	1	606,667
Non-cash interest expense	−722,763	0	—	−2	−757,021
Change in fair value of derivative liability	2	0	—	—	—
Unrealized loss on digital assets	−588,916	0	—	—	—
Change in fair value of convertible notes	−1	0	—	—	—
Foreign currency translation, net	339,847	−121,530	—	−413,279	−493,527
TOTAL OTHER INCOME (EXPENSE), NET	−2	−638,188	3	−6	−3
LOSS BEFORE INCOME TAXES	−19	−16	−19	−13	−8
INCOME TAX EXPENSE	0	0	0	−775,051	−114,010
NET LOSS	−19	−16	−19	−14	−8
Deemed dividend on issuance of warrants	0	−6	—	−32	0
Deemed dividend on warrant exchange/modification	0	−9,793	—	—	—
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	−19	−22	—	−64	−16
Foreign currency translation adjustment, net	2	−2	712,791	−981,014	−1
TOTAL COMPREHENSIVE LOSS	−17	−24	−25	−65	−17
BASIC NET LOSS PER SHARE	−0.63	−1.17	−2.15	−33.16	−23.74
DILUTED NET LOSS PER SHARE	−0.63	−1.17	−2.15	−33.16	−23.74
Basic	30	19	—	2	656,933
Diluted	30	19	—	2	656,933

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	715,674	315,105	—	21	286,487
Restricted cash	3	0	—	—	—
Accounts receivable, net	20	13	20	24	—
Accounts receivable - related party	2	1	—	—	—
Marketable securities	46,158	21,148	20,075	14,881	11,468
Inventory	6	4	5	3	3
Loans receivable	487,638	614,473	411,858	—	—
Loans receivable - related party	0	557,473	—	—	—
Prepaid expenses and other current assets	2	1	2	2	3
Prepaid expenses and other current assets - related party	5	4	—	—	—
TOTAL CURRENT ASSETS	38	25	37	56	40
Property and equipment, net	11	10	10	2	2
Goodwill and intangible assets, net	8	8	8	706,914	485,767
Digital assets	1	0	—	—	—
Loans receivable - long term portion	3	3	—	—	—
Loans receivable - related party - long term	0	3	4	—	—
Operating lease right-of-use asset	596,779	696,166	1	1	834,468
Financing lease right-of-use asset	3,831	13,607	28,790	43,084	211,099
Advances for building's acquisition	600,000	2	2	0	—
Other assets	2	1	—	—	—
Other assets - related party	2	2	—	—	—
TOTAL ASSETS	65	54	66	68	49
Accounts payable and accrued expenses	15	11	—	—	—
Accounts payable and accrued expenses - related party	2	1	231,564	—	—
Accrued interest	786,497	221,820	—	—	—
Lines of credit	9	7	7	6	—
Notes payable	2	3	2	2	—
Notes payable - related party	11,971	10,558	11,283	10,912	—
Loans payable - related party	0	6,194	—	—	—
Convertible notes payable	2	0	—	—	381,062
Derivative liability - convertible note	1	0	0	54,293	—
Operating lease liability, current portion	222,115	196,718	285,563	239,899	138,450
Financing lease liability, current portion	3,854	11,484	27,222	24,576	73,078
Other current liabilities	6	3	3	3	1
TOTAL CURRENT LIABILITIES	38	26	24	22	30
Notes payable - long term portion	2	2	3	3	13
Convertible notes payable - long term portion	4	0	—	—	—
Operating lease liability, net of current portion	373,473	498,398	844,866	828,762	696,015
Financing lease liability, net of current portion	0	3,399	5,261	31,333	148,401
Other liabilities	3	2	2	1	0
TOTAL LIABILITIES	47	30	30	28	45
Commitments and Contingencies (see Note 14)	0	0	0	0	0
Common stock, $0.001 par value;1,500,000,000 shares authorized; 41,153,809 and 23,689,135 shares issued and 41,067,312 and 23,602,638 outstanding as of December 31, 2025 and December 31, 2024, respectively	41,154	23,689	15,983	10,606	702
Additional paid-in capital	152	142	129	112	40
Subscription receivable	0	−20	—	—	—
Treasury stock, at cost, 86,497 shares as of December 31, 2025 and December 31, 2024	−917,159	−917,159	—	—	—
Accumulated deficit	−133	−114	−92	−66	−34
Accumulated other comprehensive income/(loss)	331,503	−2	−419,844	−1	−151,621
TOTAL STOCKHOLDERS' EQUITY	18	25	36	39	4
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	65	54	66	68	49

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization expense	1	1	—	103,194	352,422
Amortization of right-of-use assets	8,289	29,883	23,686	85,696	97,270
Bad debt expense	6	5	12	6	1
Impairment charges	162,785	454,280	0	—	—
Unrealized loss on crypto assets	588,916	0	—	—	—
Lease expense	264,677	286,765	—	—	—
Interest on finance leases	528	2,066	2,903	16,467	11,576
Stock based compensation	2	2	577,931	24,401	6
Deferred income taxes	22,722	−11,843	78,553	780,099	−714,108
Gain on net change in fair value of equity investments	−21,368	−2,470	—	—	—
Gain on conversion of debt	−68,609	0	—	—	—
Revenue reversals	464,610	0	—	—	—
Actuarial gains/(losses)	−48,335	0	—	—	—
Accounts receivable, net	−5	1	−5	−3	−6
Accounts receivable - related party	−1	−136,028	1	−170,815	97,234
Inventory	−829,975	146,451	−890,903	−485,469	−89,582
Prepaid expenses and other current assets	−560,891	−1	—	−894,893	−3
Prepaid expenses and other current assets - related party	−332,399	−1	−913,574	−375,311	—
Accounts payable and accrued expenses	2	−205,791	644,838	2	3
Accounts payable and accrued expenses - related party	2	1	—	—	—
Accrued interest	545,030	69,070	—	—	—
Lease liabilities	−265,148	−285,945	−373,816	−210,781	−231,900
Other current liabilities	2	141,204	−1	−320,420	1
Other liabilities	350,859	322,705	—	—	−231,900
NET CASH USED IN OPERATING ACTIVITIES	−8	−8	−16	−15	−7
Proceeds from loan receivable	137,963	468,974	806,464	351,474	63,699
Purchase of digital assets	−2	0	—	—	—
Purchase of intangible assets	−97,143	−849,168	—	—	—
Purchase of property and equipment	−55,675	−418,075	−1	−74,207	−581,398
NET CASH USED IN INVESTING ACTIVITIES	−2	−798,269	−14	−21,497	−826,817
Proceeds from convertible note payable	10	0	—	0	600,000
Payment of note payable	−2	−1	—	−421,373	−605,387
Proceeds from note payable	1	865,600	1	487,098	591,500
Payment of related party loan	−6,766	−25,968	0	−5	0
Proceeds from related party loan	0	19,476	0	4	7
Payment of lines of credit	−27	−25	−2	−12	−24
Proceeds from lines of credit	28	26	20	22	24
Proceeds from the sale of common stock	5	649,039	0	6	0
Proceeds from the exercise of warrants	0	4	—	11	0
Payments of financing fees	−2	−391,575	−717,888	−3	0
Payments of finance lease liability	−9,709	−35,062	−27,786	−99,906	−92,105
NET CASH PROVIDED BY FINANCING ACTIVITIES	14	5	13	35	7
Effect of exchange rate changes on cash	−448,834	−49,471	−214,139	307,044	314,306
NET CHANGE IN CASH	3	−4	−17	20	−341,908
Cash	715,674	315,105	—	—	—
Restricted Cash	3	0	—	—	—
Total Cash and Restricted Cash	3	315,105	—	—	—
Interest	947,139	704,839	406,885	588,051	2
Income tax	0	0	—	0	0
Debt discount on convertible notes	−3	0	—	—	—
Derivative recorded	3	0	—	—	—
Closing of acquisition of Cloudscreen	0	637,080	—	—	—
Deemed dividend upon warrant exchange	0	6	—	—	—
Common stock issued for convertible notes payable	441,164	0	—	—	—
Common stock issued for notes payable	224,791	0	—	—	—
Common stock issued in exchange for debt	2	0	—	—	—
Common stock issued to employees	1	695,405	—	—	—
Common stock issued to consultants	1	994,160	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Cosmos Health Inc.'s CIK number?

Cosmos Health Inc.'s SEC CIK number is 0001474167 (1474167). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Cosmos Health Inc.'s SEC filings?

All of Cosmos Health Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Cosmos Health Inc. last report earnings?

Cosmos Health Inc. (COSM) most recently filed an earnings 8-K with the SEC on May 22, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001477932-26-003403). This is Cosmos Health Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Cosmos Health Inc.'s most recent earnings 8-K?

Cosmos Health Inc.'s latest earnings 8-K (Item 2.02) was filed May 22, 2026 under accession 0001477932-26-003403. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Cosmos Health Inc.'s latest earnings 8-K →
Look up any company's CIK number →